Faes Farma, S.A. Stock

Equities

FAE

ES0134950F36

Pharmaceuticals

Market Closed - BME 11:35:28 2024-04-18 am EDT 5-day change 1st Jan Change
3.175 EUR +0.95% Intraday chart for Faes Farma, S.A. +0.32% +0.47%
Sales 2024 * 476M 507M Sales 2025 * 496M 528M Capitalization 988M 1.05B
Net income 2024 * 89M 94.72M Net income 2025 * 91M 96.85M EV / Sales 2024 * 2.1 x
Net Debt 2024 * 9.8M 10.43M Net cash position 2025 * 64.45M 68.59M EV / Sales 2025 * 1.86 x
P/E ratio 2024 *
10.9 x
P/E ratio 2025 *
10.7 x
Employees 1,748
Yield 2024 *
4.88%
Yield 2025 *
4.96%
Free-Float 91.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.95%
1 week+0.32%
Current month+0.95%
1 month+7.81%
3 months+2.25%
6 months+5.83%
Current year+0.47%
More quotes
1 week
3.11
Extreme 3.105
3.18
1 month
2.93
Extreme 2.93
3.20
Current year
2.91
Extreme 2.91
3.27
1 year
2.87
Extreme 2.865
3.44
3 years
2.87
Extreme 2.865
4.29
5 years
2.87
Extreme 2.865
5.48
10 years
1.61
Extreme 1.6127
5.48
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Chief Executive Officer - -
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 65 18-06-18
Chairman - 91-05-15
Director/Board Member - 94-06-25
More insiders
Date Price Change Volume
24-04-18 3.175 +0.95% 150,305
24-04-17 3.145 +0.32% 123,431
24-04-16 3.135 -1.26% 221,849
24-04-15 3.175 +0.63% 171,991
24-04-12 3.155 -0.32% 254,172

Delayed Quote BME, April 18, 2024 at 11:35 am EDT

More quotes
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
3.175 EUR
Average target price
3.708 EUR
Spread / Average Target
+16.77%
Consensus

Quarterly revenue - Rate of surprise